Agomab Therapeutics (AGMB) Payables (2024 - 2025)
Agomab Therapeutics (AGMB) posted quarterly Payables of $12.0 million for Q4 2025, up 38.88% year-over-year from $8.6 million in Q4 2024, and up 38.88% quarter-over-quarter from $8.6 million in Q4 2024.
Agomab Therapeutics (AGMB) Payables (2024 - 2025) Analysis & Trends
Agomab Therapeutics' Payables history runs 2 years deep, the most recent figure standing at $12.0 million for Q4 2025.
- In Q4 2025, Payables rose 38.88% year-over-year to $12.0 million; the TTM figure through Dec 2025 stood at $12.0 million (up 38.88% YoY), while the FY2025 annual figure was $12.0 million, up 37.12% from the prior year.
- Payables for Q4 2025 stood at $12.0 million, up from $8.6 million in the prior quarter.
- The five-year high for Payables was $12.0 million in Q4 2025, with the low at $8.6 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 35.57 Mn |
| 10 | Agomab Therapeutics | 7.20 Mn | -250.38 Mn | - | 13.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 11.95 Mn |
| Dec 31, 2024 | 8.60 Mn |